Compare CRBU & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRBU | MSLE |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.3M | 144.6M |
| IPO Year | 2021 | 2007 |
| Metric | CRBU | MSLE |
|---|---|---|
| Price | $0.44 | $6.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $5.75 | ★ $24.17 |
| AVG Volume (30 Days) | ★ 5.3M | 43.7K |
| Earning Date | 11-16-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.64 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $145.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $5.44 |
| 52 Week High | $2.49 | $13.39 |
| Indicator | CRBU | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 25.23 | 40.29 |
| Support Level | N/A | $6.60 |
| Resistance Level | $0.58 | $10.58 |
| Average True Range (ATR) | 0.04 | 0.51 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 17.99 | 45.16 |
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.